Data protection Impressum

Newsroom

Oculis, the Lausanne-based biopharmaceutical company focused on ophthalmology and neuro-ophthalmology, will acquire all worldwide development and commercial rights to Privosegtor from Accure, terminating its existing license agreement.

Oculis acquires worldwide rights to its Privosegtor candidate

17 August 2026

Researchers at EPFL, with colleagues from the University of Geneva, Geneva University Hospitals and Zurich, have developed VirTues, an AI foundation model for tissue biology that analyzes tumor tissue across many cancer types, with results published in Nature.

EPFL’s VirTues AI model maps tumor tissue across cancer types

17 August 2026

NVIDIA has launched Halos for Robotics, a full-stack safety system for physical AI, with Fribourg-based CertX and Geneva-headquartered SGS among the certification bodies recognizing its accredited inspection lab.

CertX and SGS join NVIDIA’s robotics safety program

12 August 2026

LS Instruments, a Fribourg-based maker of advanced light scattering and microrheology instruments, has been acquired by Germany's Postnova Analytics, with operations, manufacturing and the existing team remaining at its Fribourg headquarters.

LS Instruments joins Postnova Analytics while keeping its operations in Fribourg

12 August 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (July 2026)

3 August 2026

AB2 Bio has received a USD 30 million payment after Japanese pharmaceutical company Nippon Shinyaku exercised its option to commercialize Tadekinig alfa in the United States, with up to USD 600 million in further milestone and royalty payments.

AB2 Bio receives USD 30 million as Nippon Shinyaku takes up US rights

3 August 2026

Hilo closes a USD 19 million Series B extension to fuel its US expansion

3 August 2026

Actival, a CSEM spin-off based in Neuchâtel, has been awarded a CHF 1.4 million grant from Innosuisse to accelerate the development and market launch of its patented Active Splints, a new generation of dental aligners that dispense antibacterial fluid and fluoride.

Actival secures a CHF 1.4 million Innosuisse grant for its smart dental aligners

3 August 2026

MoleSense and Impli, both based at the Biopôle life sciences campus, have been selected by Germany's Federal Agency for Breakthrough Innovation to develop biosensors capable of continuously measuring at least four hormones over seven days.

MoleSense and Impli selected for the SPRIND Challenge on continuous hormone monitoring

3 August 2026

Immitra Bio, based in Plan-les-Ouates in the canton of Geneva, has closed an upsized CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform and its lead candidate for an inherited anemia.

Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform

3 August 2026

1 2 3 4 5 6 7 … 97